Literature DB >> 26422564

Sarcoid in cancer patients: clinical characteristics and associated disease status.

Ana P Kiess1, Hangjun Wang, William D Travis, Joachim Yahalom.   

Abstract

BACKGROUND: The increased risk of cancer in patients with sarcoidosis is well established, but there is little information regarding sarcoid diagnosed during or following cancer. The purpose of this study is to describe and analyze the disease status and events associated with the diagnosis of sarcoid in cancer patients.
METHODS: At a large cancer center, we identified 64 patients with a pathologic diagnosis of sarcoid-like granuloma during or following a diagnosis of malignancy. Pathology specimens were re-examined by experts, and clinical and imaging information were reviewed. Disease-related events including recurrence, progression, death, and second malignancy were analyzed.
RESULTS: The most common primary malignancies were breast (17%), lymphoma (16%), lung (13%), and testicular cancer (11%). Thirty-six out of 64 patients (56%) were diagnosed with sarcoid within 10 months of their primary malignancy, whereas 28 (44%) were diagnosed with sarcoid in follow-up, including 15/28 without evidence of disease, 6 with associated diagnosis of recurrence, 5 with associated diagnosis of second malignancy, 1 with stable disease, and 1 with progressive disease. Sarcoid biopsy sites included mediastinal nodes (59%), hilar nodes (13%), lung (30%), and other nodes (17%), and the reason for biopsy was usually abnormal imaging (66%). Sarcoid and tumor were co-localized in 34%. Including long-term follow-up events, sarcoid was present in association with 10 of 19 recurrences (53%) and 8 of 12 second malignancies (67%).
CONCLUSION: While sarcoid often presents at initial diagnosis or staging of cancer, in a significant number of patients, it appears in association with recurrence or second malignancy.

Entities:  

Mesh:

Year:  2015        PMID: 26422564

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  7 in total

1.  Intrascrotal and osseous sarcoidosis mimicking intrascrotal organ cancer and bony metastasis.

Authors:  Shin-Ichi Nureki; Eishi Miyazaki; Mari Yamasue; Ryuichi Takenaka; Masaru Ando; Jun-Ichi Kadota
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Selected Giant Cell Rich Lesions of the Temporal Bone.

Authors:  Anthony P Martinez; Jorge Torres-Mora
Journal:  Head Neck Pathol       Date:  2018-08-01

3.  The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.

Authors:  Eva Novosadova; Alzbeta Chabronova; Vitezslav Kolek; Martin Petrek; Zdenka Navratilova
Journal:  Mediators Inflamm       Date:  2016-12-05       Impact factor: 4.711

4.  Sarcoidosis and colon cancer: a possible association.

Authors:  Anna Agnese Stanziola; Giovanna Caccavo; Nicolina De Rosa; Maria D'Amato; Rajeev Saggar; Giuseppe Spadaro; Antonio Ponticiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

5.  Presence of concurrent sarcoid-like granulomas indicates better survival in cancer patients: a retrospective cohort study.

Authors:  Mukunthan Murthi; Keiichiro Yoshioka; Jeong Hee Cho; Sixto Arias; Elio Danna; Moe Zaw; Greg Holt; Koichiro Tatsumi; Takeshi Kawasaki; Mehdi Mirsaeidi
Journal:  ERJ Open Res       Date:  2020-10-26

6.  A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas.

Authors:  Andrea P Espejo; Jeremy L Ramdial; Breelyn A Wilky; Darcy A Kerr; Jonathan C Trent
Journal:  Rare Tumors       Date:  2018-07-18

7.  Diagnosis distribution in cases with granulomatous inflammation in lung, pleura, and lymph node biopsies: an experience from a tertiary level single center chest diseases and thoracic surgery hospital.

Authors:  Selma Aydogan Eroglu; Tekin Yildiz; Esin Sonkaya; Murat Kavas; Fatma Ozbaki; Lale Sertçelik; Aycim Sen; Tulin Sevim
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 0.670

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.